» Articles » PMID: 12930377

Donor Dependent, Interferon-gamma Induced HLA-DR Expression on Human Neutrophils in Vivo

Overview
Date 2003 Aug 22
PMID 12930377
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Neutrophils are effector cells of innate immune responses. Stimulated by interferon-gamma (IFN-gamma) to express HLA-DR, neutrophils acquire accessory cell functions for superantigen-mediated T cell activation. In vitro HLA-DR induction on neutrophils varies in a functionally relevant way as levels of MHC class II expression and magnitude of neutrophil induced T cell responses are correlated functions. The aim of this study was to assess whether IFN-gamma induces HLA-DR on human neutrophils in a donor dependent fashion in vivo and to define regulatory events operative in MHC class II expression of neutrophils. In vivo administration of rhIFN-gamma in 55 patients with renal cell carcinoma resulted in a varying increase of HLA-DR on neutrophils. By setting a cut-off for response at>10% HLA-DR positive neutrophils, HLA-DR responders (51%) were as frequent as nonresponders (49%). In vivo kinetic studies revealed a peak expression of HLA-DR on neutrophils 48 h after rhIFN-gamma application, while nonresponders remained HLA-DR negative over a 72-h period. In vitro IFN-gamma stimulated neutrophils recapitulated the response profiles observed in vivo. No differences in IFN-gamma dependent CD64 and invariant chain expression, and IFN-gamma serum levels were observed among the response subgroups. HLA-DR mRNA was detected in neutrophils from rhIFN-gamma treated responders and nonresponders, HLA-DR protein solely in lysates of responder neutrophils. IFN-gamma stimulated HLA-DR expression on neutrophils is subject to donor dependent variations in vivo, which result from rather post-transcriptional than transcriptional regulation. Due to their abundance in inflammatory reactions heterogeneous HLA-DR expression by neutrophils could determine the outcome of superantigen-driven diseases.

Citing Articles

Lower leukocytes pretreatment as a possible risk factor for therapy-induced leukopenia in interferon-beta-treated patients with multiple sclerosis.

Protopapa M, Schmaul S, Schraad M, Pape K, Zipp F, Bittner S Ther Adv Neurol Disord. 2024; 17:17562864241286497.

PMID: 39479177 PMC: 11523160. DOI: 10.1177/17562864241286497.


Unveiling signaling pathways inducing MHC class II expression in neutrophils.

Forrer P, Palianina D, Stuhler C, Kreuzaler M, Roux J, Li J Front Immunol. 2024; 15:1444558.

PMID: 39403371 PMC: 11472776. DOI: 10.3389/fimmu.2024.1444558.


Complex role of neutrophils in the tumor microenvironment: an avenue for novel immunotherapies.

Zhang M, Qin H, Wu Y, Gao Q Cancer Biol Med. 2024; 21(10).

PMID: 39297568 PMC: 11523270. DOI: 10.20892/j.issn.2095-3941.2024.0192.


Circulating Neutrophil Profiles Undergo a Dynamic Shift during Metabolic Dysfunction-Associated Steatohepatitis (MASH) Progression.

Maretti-Mira A, Salomon M, Chopra S, Yuan L, Golden-Mason L Biomedicines. 2024; 12(5).

PMID: 38791066 PMC: 11117983. DOI: 10.3390/biomedicines12051105.


Neutrophils at the Crossroads: Unraveling the Multifaceted Role in the Tumor Microenvironment.

Awasthi D, Sarode A Int J Mol Sci. 2024; 25(5).

PMID: 38474175 PMC: 10932322. DOI: 10.3390/ijms25052929.


References
1.
Kanazawa S, Okamoto T, Peterlin B . Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection. Immunity. 2000; 12(1):61-70. DOI: 10.1016/s1074-7613(00)80159-4. View

2.
Lichtenberger C, Zakeri S, Baier K, Willheim M, Holub M, Reinisch W . A novel high-purity isolation method for human peripheral blood neutrophils permitting polymerase chain reaction-based mRNA studies. J Immunol Methods. 1999; 227(1-2):75-84. DOI: 10.1016/s0022-1759(99)00076-9. View

3.
Yamashiro S, Wang J, Yang D, Gong W, Kamohara H, Yoshimura T . Expression of CCR6 and CD83 by cytokine-activated human neutrophils. Blood. 2000; 96(12):3958-63. View

4.
Kwak B, Mulhaupt F, Myit S, Mach F . Statins as a newly recognized type of immunomodulator. Nat Med. 2000; 6(12):1399-402. DOI: 10.1038/82219. View

5.
Radsak M, Iking-Konert C, Stegmaier S, Andrassy K, Hansch G . Polymorphonuclear neutrophils as accessory cells for T-cell activation: major histocompatibility complex class II restricted antigen-dependent induction of T-cell proliferation. Immunology. 2000; 101(4):521-30. PMC: 2327116. DOI: 10.1046/j.1365-2567.2000.00140.x. View